ReviewTherapeutic delivery2013
Current progress on aptamer-targeted oligonucleotide therapeutics.
Review in Therapeutic delivery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.Pharmacological reviews · 2020Pooled it
- Surface-enhanced Raman scattering detection of matrix metalloproteinase-9 via an aptamer-based plasmonic ruler.Analytical and bioanalytical chemistry · 2026Article
- Enhancing the intracellular delivery of antisense oligonucleotides (ASO) : a comparative study of aptamer, vitamin E, and cholesterol ASO conjugates.RSC advances · 2025Article
- Bridging biological samples to functional nucleic acid biosensor applications: current enzymatic-based strategies for single-stranded DNA generation.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Review
- A novel aptamer-based small RNA delivery platform and its application to cancer therapy.Genes & diseases · 2023Article
- The emerging roles of long non-coding RNA in host immune response and intracellular bacterial infections.Frontiers in cellular and infection microbiology · 2023Review
- Targeted delivery of doxorubicin and therapeutic FOXM1 aptamer to tumor cells using gold nanoparticles modified with AS1411 and ATP aptamers.Iranian journal of basic medical sciences · 2023Article
- Nanoparticle-mediated selective Sfrp-1 silencing enhances bone density in osteoporotic mice.Journal of nanobiotechnology · 2022Article
- Synthesis and Exon-Skipping Properties of a 3'-Ursodeoxycholic Acid-Conjugated Oligonucleotide TargetingMolecules (Basel, Switzerland) · 2021Article
- Review
- Gene regulation by long non-coding RNAs and its biological functions.Nature reviews. Molecular cell biology · 2021Review
- Aptamers and antibodies: rivals or allies in cancer targeted therapy?Exploration of targeted anti-tumor therapy · 2021Review
- Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers.Frontiers in chemistry · 2021Review
- Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer.Molecular therapy. Nucleic acids · 2019Article
- Silencing RORγt in Human CD4Scientific reports · 2019Article
- RNA inhibitors of nuclear proteins responsible for multiple organ dysfunction syndrome.Nature communications · 2019Article
- Nucleic Acid-Based Therapeutics for Pulmonary Diseases.AAPS PharmSciTech · 2018Review
- Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein.Journal of the American Chemical Society · 2018Article
- Tapping the RNA world for therapeutics.Nature structural & molecular biology · 2018Review
- The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.Molecular and cellular pediatrics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Exploiting the power of the RNAi pathway through the use of therapeutic siRNA drugs has remarkable potential for treating a vast array of human disease conditions. However, difficulties in delivery of these and similar nucleic acid-based pharmacological agents to appropriate organs or tissues, remains a major impediment to their broad clinical application. Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery vehicles for therapeutic oligonucleotides, including siRNAs. In this review, we summarize recent attractive developments in creatively employing cell-internalizing aptamers to deliver therapeutic oligonucleotides (e.g., siRNAs, miRNAs, anti-miRs and antisense oligos) to target cells. We also discuss advancements in aptamer-siRNA chimera technology, as well as, aptamer-functionalized nanoparticles for siRNA delivery. In addition, the challenges and future prospects of aptamer-targeted oligonucleotide drugs for clinical translation are further highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.